Nibec나이벡

Nibec138610· Biotech & PharmaInitiation

Nibec: Revenue Recovered in 2025, but Losses Returned in the Latest Twelve Months and the Share Price Is Down 67.0% Over a Year

Nibec, a KOSDAQ-listed biotech and pharma company, swung to an operating profit of ₩5.0B in 2025 but posted an operating loss of ₩1.9B over the twelve months to H1 2026. The shares closed at ₩15,100 on 2026-10-16, down 67.0% over one year and 72.2% below the 52-week high of ₩54,300.

Oct 18, 20260 views